Skip to content

Efficacy of topical 2% Rebamipide 2% eyedrop in dry eye post -cataract surgery

Efficacy of topical 2% Rebamipide 2% eyedrop in dry eye post -cataract surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008193
Enrollment
66
Registered
2023-02-16
Start date
2023-01-19
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients can participate in this study if all of the following criteria are met.1) Adults over 19 years of age 2) Those who underwent binocular cataract surgery at the hospital and observed it for more than a month 3) Dry eyes are diagnosed if one or more of the following criteria are satisfied. (A) A person who has symptoms of dry eye at the time of one month of binocular cataract surgery. (B) If tear film destruction time (TBUT) is less than 10 seconds. (C) If more than 5 corneal spots on eye surface staining are observed 4) Ocular surface disease index (OSDI) score 13 points or more 5) A person who voluntarily agreed to participate in this study.

Exclusion criteria

Exclusion criteria: If any of the following criteria are met, patients cannot participate in this study.1) If complications occur during or after cataract surgery 2) No meibum secretion at all due to blocked meibomian glands in the upper and lower eyelids 3) Previous punctal plug or puntal cauterization history 4) Eye trauma, infection or burn history within the last 3 months 6) usage of topical cyclosporine A 0.05% in the last 3 months 7) History of Sjogren's syndrome, giant papillary conjunctivitis or corneal limbal epithelial cell deficiency 8) Pregnant or lactating women 9) allergic to fluorescein or eye anesthetics 10) Other subjects who are thought to be unsuitable by investigator

Design outcomes

Primary

MeasureTime frame
O cular Surface Disease Index ; OSDI questionnare;Tear Break Up Time ; TBUT; NEI scale using fluorescein sodium;Meibomian gland dysfunction grade;Matrixmetalloproteinase -9 (MMP -9) level;Tear Osmaolarity test;Schirmer test

Secondary

MeasureTime frame
visual acuity;intraocular pressure;Refractive index

Countries

Korea, Republic of

Contacts

Public ContactJae Yong Kim

Asan Medical Center

jykim2311@amc.seoul.kr+82-2-3010-3680

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026